Compare FA & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | IDYA |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2021 | 2019 |
| Metric | FA | IDYA |
|---|---|---|
| Price | $15.55 | $35.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $19.75 | ★ $49.18 |
| AVG Volume (30 Days) | 547.9K | ★ 948.9K |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,461,496,000.00 | $214,834,000.00 |
| Revenue This Year | $85.07 | $2,662.86 |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 93.41 | ★ 5377.66 |
| 52 Week Low | $11.95 | $13.45 |
| 52 Week High | $20.28 | $37.08 |
| Indicator | FA | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 56.05 |
| Support Level | $14.47 | $33.11 |
| Resistance Level | $15.65 | $34.45 |
| Average True Range (ATR) | 0.47 | 1.24 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 91.59 | 47.11 |
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.